Clinical trials: Regorafenib
Stage III (IIIB or IIIC) Colon Cancer
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
This study is a randomized, double-blind, post-chemotherapy, adjuvant phase III clinical trial. The primary aim of this study is to determine the value of regorafenib in improving disease-free survival (DFS).
- Trial name
- ARGO (NCT02664077)
- Testing
- Regorafenib
- Where
- 51 sites in United States
- Volunteers
- 34 people
- Sponsor
- NSABP Foundation Inc
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Regorafenib
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Trial name
- NCT05048017
- Testing
- Regorafenib, PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Tumors
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.
- Trial name
- NCT00960258
- Testing
- Regorafenib (BAY73-4506)
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Metastatic Colorectal Cancer
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer- A Retrospective, Observational Study
- Trial name
- NCT05023720
- Testing
- nonintervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Henan Cancer Hospital
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
TAS 102, Regorafenib
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.
- Conditions
- TAS 102, Regorafenib, Fruquintinib, Gastrointestinal Tumours
- Trial name
- NCT05993702
- Testing
- regorafenib, fruquintinib
- Volunteers
- 45 people
- Sponsor
- China Medical University, China
Colorectal Cancer
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal…
- Trial name
- REGAL-1 (NCT02116894)
- Testing
- PF-03446962, Regorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic…
- Trial name
- NCT05917431
- Testing
- SBRT plus tislelizumab and regorafenib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Colorectal Cancer
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
In recent years, anti-angiogenic agents have been incorporated into clinical practice for the treatment of metastatic CRC, leading to improvements in progression-free survival and overall survival.
- Trial name
- NCT01949194
- Testing
- Regorafenib
- Where
- 5 sites in Canada
- Volunteers
- 48 people
- Sponsor
- Gerald Batist
Colorectal Cancer Stage IV, No Evidence of Disease State
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state.
- Trial name
- VIVA (NCT05382741)
- Testing
- Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules
- Where
- Italy
- Volunteers
- 182 people
- Sponsor
- Ospedale Policlinico San Martino
Sintilimab, Cetuximab, Regorafenib,Combine,mCRC
Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)
The incidence of colorectal cancer ranks the third in the world and the mortality ranks the second in the world. The incidence and mortality of colorectal cancer have increased in China in the past decade.
- Trial name
- NCT04745130
- Testing
- Sintilimab，regofinib，cetuximab, KRAS BRAF mutant Sintilimab + regafinil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Osteosarcoma, Osteosarcoma in Children
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
- Trial name
- NCT04803877
- Testing
- Regorafenib 40 MG, Regorafenib 20MG, Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Objective Response Rate, Progression-free Survival
Real-world Study for Patients With Advanced Hepatobiliary Tumors
The investigators design a large sample size study in the real-world to explore whether targeted therapy and immunotherapy can improve the survival, quality of life and drug safety of patients with advanced hepatobiliary tumors…
- Conditions
- Objective Response Rate, Progression-free Survival, Overall Survival, Disease Control Rate
- Trial name
- NCT03892577
- Testing
- Precision oncology including targeted therapy and immunotherapy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma (HCC)
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
The goal of this clinical trial is to learn if lenvatinib or regorafenib can help treat people with advanced liver cancer (hepatocellular carcinoma, HCC) that cannot be removed with surgery after first treatment with…
- Trial name
- REVIVE (NCT07495579)
- Testing
- Lenvatinib, regorafenib
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Asan Medical Center
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Gastrointestinal Stromal Tumors
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
To learn if regorafenib can help to control the disease.
- Trial name
- NCT06087263
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
- Trial name
- REGIRI (NCT03722108)
- Testing
- Regorafenib and Irinotecan, Irinotecan
- Where
- 27 sites in France
- Volunteers
- 89 people
- Sponsor
- UNICANCER
Colorectal Neoplasms
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
This is a phase III B, prospective, interventional, open-label, single-arm, multicenter study to provide regorafenib to subjects diagnosed with metastatic colorectal cancer who have failed after standard therapy and for whom no…
- Trial name
- CONSIGN (NCT01538680)
- Testing
- Regorafenib (BAY73-4506)
- Where
- 207 sites in United States, Australia and 23 more
- Sponsor
- Bayer